FDAnews Announces — A Biosimilar by Any Other Name: What the FDA’s Draft Rules Mean for You Webinar, Oct. 22, 2015

Share Article

In August, the FDA published it’s highly anticipated draft guidance on naming biosimilars. Massive controversy has erupted over whether biosimilars need to be named differently from their originals, and if so, how.

A Biosimilar by Any Other Name:
What the FDA’s Draft Rules Mean for You
**FDAnews Webinar**
Oct. 22, 2015 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/abiosimilarbyanyothername

It’s been a long time coming.

In August, the FDA published it’s highly anticipated draft guidance on naming biosimilars. Massive controversy has erupted over whether biosimilars need to be named differently from their originals, and if so, how.

What do doctors and patients need to know, and what will just confuse them? The WHO and the EMA have their own alternative naming schemes under consideration. China, Australia and Mexico are weighing in as well.

In this webinar, Kevin Nelson, an expert in pharmaceutical intellectual property law, will explain:

  •     The genesis of the issue: how small molecule products are named and why
  •     The arguments and policy concerns on both sides of the naming dispute prior to the FDA’s guidance
  •     Deep dive into the FDA’s guidance: what questions were answered and what questions remain
  •     Naming in practice: Sandoz’s Zarxio, a.k.a. filgrastim-sndz — why the FDA needed to implement a naming guidance now
  •     Putting the cart before the horse: what about interchangeability?

Get the whole story on biosimilars today, and be ready for this new field as it develops.

Meet Your Presenter:
Kevin Nelson
Partner, Duane Morris LLP
Kevin M. Nelson practices in the area of intellectual property with a focus on complex pharmaceutical patent litigation. For the past 12 years, Mr. Nelson has represented generic drug companies in patent litigation brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. He has also represented clients before the U.S. Food and Drug Administration in regulatory matters and in opposing citizen petitions. In addition, Mr. Nelson has advised clients regarding biosimilars applications and litigation.

Who Will Benefit:

  •     Compliance officers
  •     Consultants/service providers
  •     Executive management
  •     General/corporate counsel
  •     Managers
  •     Regulatory/legislative affairs professionals
  •     Sales/marketing personnel
  •     Strategic planning and business development staff

Conference Details:
A Biosimilar by Any Other Name:
What the FDA’s Draft Rules Mean for You
**FDAnews Webinar**
Oct. 22, 2015 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/abiosimilarbyanyothername

Tuition:
$287 per site
Easy Ways to Register:
Online:     http://www.fdanews.com/abiosimilarbyanyothername
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website